Oryzon is the first Spanish company in functional genomics. Incorporated in 2000, the company is a paradigm of high growth in the emergent Spanish Biotech sector.

The company at a glance:

• Venture Backed (Najeti SCR)
• Close to 80  employees. A young and multinational team
• 6,5 M € of revenues in 2008
• Five consecutive years on net profits
• 6 Affiliated companies
• An IPO oriented funding strategy
• A Biomarker discovery company focused in oncology and neurodegeneration
• Extending activities from diagnostics to therapy through biologics
• Strong appetite for international partnerships (companies/academy)
• Ready to CO-Develop new targets oriented to product development
• Happy to in-license IP (targets in oncology / CNS / Technology)
• Wanting to Attract human talent